Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.04.4289 on June 5 2006

Journal of Clinical Oncology, Vol 24, No 19 (July 1), 2006: pp. 3107-3112
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Redfern, C. H.
Right arrow Articles by Bender, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Redfern, C. H.
Right arrow Articles by Bender, J. F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo, John J. Densmore, Peter R. Holman, Nalini Janakiraman, John P. Leonard, Richard L. Levy, Richard G. Just, Mitchell R. Smith, Fred P. Rosenfelt, Peter H. Wiernik, William D. Carter, Daniel P. Gold, Teresa J. Melink, John C. Gutheil, John F. Bender

From Sharp Healthcare; University of California; Favrille Inc, San Diego; Medical Group of North County, Vista; Scripps Cancer Center, La Jolla; Tower Hematology/Oncology Medical Group, Los Angeles, CA; University of Florida, Jacksonville, FL; University of Virginia, Charlottesville, VA; Henry Ford Hospital, Detroit, MI; New York Hospital-Cornell Medical Center, New York; Our Lady of Mercy Medical Center, Bronx, NY; Oncology/Hematology Care Inc, Cincinnati, OH; and Fox Chase Cancer Center, Philadelphia, PA

Address reprint requests to John F. Bender, PharmD, Favrille Inc, 10421 Pacific Center Ct, San Diego, CA 92121; e-mail: john.bender{at}favrille.com

PURPOSE: To evaluate idiotype (Id) vaccination as a single agent in previously treated patients with indolent non-Hodgkin’s lymphoma.

PATIENTS AND METHODS: Patients underwent biopsy for determination of their lymphoma-specific Id sequence. Recombinant Id protein was manufactured and covalently linked with keyhole limpet hemocyanin (KLH) to generate Id/KLH. Patients received Id/KLH 1 mg on day 1 subcutaneously, with granulocyte-macrophage colony-stimulating factor 250 µg on days 1 to 4, monthly for 6 months. Booster injections were administered until progression. Both clinical and immune responses were evaluated.

RESULTS: Thirty-two previously treated patients received at least one injection of Id/KLH, and 31 were assessed for efficacy. Responses were observed in four patients (one complete response and three partial responses). Median time to onset of response was 5.9 months (range, 2.3 to 14.1 months). Median duration of response has not been reached but should be at least 19.4 months (range, 10.4 to 27.2+ months). Median time to progression is 13.5 months. The most common adverse events were mild to moderate injection site reactions. Six (67%) of nine patients tested demonstrated a cellular immune response, and four (20%) of 20 patients demonstrated an antibody response against their Id.

CONCLUSION: This trial demonstrates that Id/KLH alone can induce tumor regression and durable objective responses. Further study of Id/KLH is recommended in other settings where efficacy may be further enhanced as in first-line therapy or after cytoreductive therapy.

Presented in part at the 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002; the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003; and the Pan-Pacific Lymphoma Conference, Kauai, HI, July 11-15, 2005.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. G. Ramsay, A. J. Clear, G. Kelly, R. Fatah, J. Matthews, F. MacDougall, T. A. Lister, A. M. Lee, M. Calaminici, and J. G. Gribben
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Blood, November 19, 2009; 114(21): 4713 - 4720.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Qin, S.-c. Cha, S. S. Neelapu, Y. Lou, J. Wei, Y.-J. Liu, and L. W. Kwak
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity
Blood, November 5, 2009; 114(19): 4142 - 4149.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Freedman, S. S. Neelapu, C. Nichols, M. J. Robertson, B. Djulbegovic, J. N. Winter, J. F. Bender, D. P. Gold, R. G. Ghalie, M. E. Stewart, et al.
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
J. Clin. Oncol., June 20, 2009; 27(18): 3036 - 3043.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Blood, June 4, 2009; 113(23): 5743 - 5746.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. P. Hilchey, O. Hyrien, T. R. Mosmann, A. M. Livingstone, J. W. Friedberg, F. Young, R. I. Fisher, R. J. Kelleher Jr, R. B. Bankert, and S. H. Bernstein
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
Blood, April 16, 2009; 113(16): 3809 - 3812.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Blood, January 1, 2009; 113(1): 18 - 27.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. W. Leitner, M. C. Baker, T. L. Berenberg, M. C. Lu, P. J. Yannie, and M. C. Udey
Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen
Blood, January 1, 2009; 113(1): 37 - 45.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman
Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas
J. Immunol., September 15, 2008; 181(6): 4131 - 4140.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al.
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
PNAS, July 22, 2008; 105(29): 10131 - 10136.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]


Home page
aacredbookHome page
R. Houot and R. Levy
Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 3 - 11.
[Full Text] [PDF]


Home page
BloodHome page
M. C. Popescu, R. J. Robb, M. M. Batenjany, L. T. Boni, M. E. Neville, R. W. Pennington, S. S. Neelapu, and L. W. Kwak
A novel proteoliposomal vaccine elicits potent antitumor immunity in mice
Blood, June 15, 2007; 109(12): 5407 - 5410.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials
J. Immunol., February 15, 2007; 178(4): 1975 - 1979.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online